On October 31^st the pan-Canadian Oncology Drug Review Expert Review Committee (pERC) of Canada’s Drug Agency (CDA-AMC) decided not to recommend TALVEY (talquetamab) for reimbursement. 

The pERC’s draft decision states that due to the limited data available for their review and the nature of its side effects, public drug plans should not fund talquetamab for adults with relapsed/refractory myeloma. Myeloma Canada will provide feedback to pERC on the draft decision and remain engaged in advocating for improved access to new myeloma treatments such as talquetamab across Canada.

This decision applies to all provinces and territories except Quebec. The Institut national d’excellence en santé et en services sociaux (INESSS) which makes recommendations in Quebec has not yet issued a decision on talquetamab.  

Learn more.